Clinical trials: PTSD
PTSD
12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
This is an open-label, extension trial designed to evaluate safety over 12 additional weeks of TNX-102 SL therapy taken daily at bedtime for the treatment of PTSD.
- Trial name
- NCT03110575
- Testing
- TNX-102 SL
- Where
- 32 sites in United States
- Volunteers
- 190 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) - a sublingual formulation of cyclobenzaprine.
- Trial name
- RECOVERY (NCT03841773)
- Testing
- TNX-102 SL
- Where
- 30 sites in United States
- Volunteers
- 192 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD
A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Evaluate the long-term safety of TNX-102 SL 5.6 mg taken daily at bedtime over an additional 40 weeks in patients with PTSD who have participated in a double-blind lead-in study and completed an initial 12-week open-label…
- Trial name
- P306 (NCT03508700)
- Testing
- TNX-102 SL 5.6 mg
- Where
- 16 sites in United States
- Volunteers
- 93 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD
Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD.
- Trial name
- NCT04030169
- Testing
- Midomafetamine HCl
- Where
- 6 sites in Czechia, Germany and 3 more
- Volunteers
- 21 people
- Sponsor
- MAPS Europe B.V.
PTSD, Generalized Anxiety Disorder
Feasibility and ML Training Investigation of the Senseye DT for Diagnosis of Adults with PTSD
The aim of this study is to obtain data on the feasibility of the Senseye Diagnostic Tool (DT) to assess the presence and severity of post-traumatic stress disorder (PTSD) symptoms.
- Conditions
- PTSD, Generalized Anxiety Disorder, Major Depressive Disorder
- Trial name
- NCT05717439
- Testing
- CAPS-5-R, Senseye DT
- Where
- 5 sites in United States
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Senseye, Inc.
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
PTSD
Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD
The goal of this long-term follow-up study is to measure how long effects of MDMA-assisted therapy last in participants with PTSD who were treated in a prior Phase 3 clinical trial of MDMA-assisted therapy.
- Trial name
- MPLONG (NCT05066282)
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 186 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans
The goal of this clinical trial is to learn if MDMA-assisted group therapy is safe and effective in in people with at least moderate PTSD.
- Trial name
- MPG1 (NCT05173831)
- Testing
- Midomafetamine, Therapy
- Sponsor
- Resilient Pharmaceuticals
PTSD
OM and Trauma Study
The primary purpose of this study is to use an unblinded, uncontrolled, 1-month interventional single group pilot study, to assess the possibility of Orgasmic Meditation practice being used as a possible intervention for PTSD.
- Trial name
- OMTP (NCT05577377)
- Testing
- Orgasmic Meditation
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Institute of OM Foundation
PTSD, Post Traumatic Stress Disorder
NeuroGlove PTSD Study
This is a prospective, home-based, interventional clinical study in which 6 subjects will be enrolled. Six (6) subjects who suffer from post-traumatic stress disorder will receive treatment using the NeuroGlove.
- Trial name
- NCT06050590
- Testing
- NeuroGlove
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- NeuroGlove LLC
PTSD
Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study that will investigate the efficacy and safety of two doses of TNX-102 SL -a sublingual formulation of cyclobenzaprine.
- Trial name
- AtEase (NCT02277704)
- Testing
- TNX-102 SL
- Where
- 23 sites in United States
- Volunteers
- 245 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD
Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of 5.6 mg TNX-102 SL (2 x 2.8 mg tablets)-a sublingual formulation of cyclobenzaprine.
- Trial name
- HONOR (NCT03062540)
- Testing
- TNX-102 SL
- Where
- 44 sites in United States
- Volunteers
- 358 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
Post-traumatic Stress Disorder (PTSD)
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
- Trial name
- NCT05189977
- Testing
- Propranolol, Prazosin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
PTSD, Sleep Disturbance
Electrical Vestibular Nerve Stimulation (VeNS) as a Method of Sleep Management in People With PTSD
This double blind randomized controlled study will enroll 20 subjects and will be conducted remotely. The study will be randomized for an 8-week period with a 1:1 active to sham device allocation.
- Conditions
- PTSD, Sleep Disturbance, Insomnia
- Trial name
- NCT04780893
- Testing
- Modius Sleep
- Volunteers
- healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
PTSD
Safety and Efficacy Study of TNX-102 SL in Participants With PTSD
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of 5.6 mg TNX-102 SL (2 x 2.8 mg tablets)-a sublingual formulation of cyclobenzaprine.
- Trial name
- NCT05372887
- Testing
- TNX-102 SL
- Where
- 3 sites in Kenya
- Sponsor
- Tonix Pharmaceuticals, Inc.
Posttraumatic Stress Disorder (PTSD), Avoidant Personality Disorder
Effectiveness of PTSD-treatment Compared to Integrated PTSD-PD-treatment in Adult Patients With Comorbid PTSD and CPD
The goal of PROSPER-C is to study effectiveness of ImRs compared to integrated SFT-ImRs in treatment-seeking, adult patients with comorbid PTSD and Cluster C Personality Disorder (CPD).
- Conditions
- Posttraumatic Stress Disorder (PTSD), Avoidant Personality Disorder, Dependent Personality Disorder, Obsessive Compulsive Personality Disorder
- Trial name
- PROSPER-C (NCT03833531)
- Testing
- ImRS, SFT
- Where
- Netherlands
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Arkin
PTSD
Studying the Clinical Research Experiences of Patients With PTSD
Clinical research participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical study may make it more difficult for patients to take part or see it…
- Trial name
- NCT05840120
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
PTSD
Senseye's OBCI Diagnostic Tool for PTSD
This pilot study will investigate the feasibility, acceptability, repeatability, accuracy and efficacy of the Senseye OBCI diagnostic tool to assess the presence and severity of PTSD symptoms and monitor response to…
- Trial name
- NCT05372523
- Testing
- CAPS-5 Assessment, Senseye OBCI
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Senseye, Inc.
PTSD
Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants with Post-Traumatic Stress Disorder (PTSD)
- Trial name
- NCT05181995
- Testing
- NYX-783
- Where
- 37 sites in United States
- Volunteers
- 121 people
- Sponsor
- Aptinyx